Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ATAI
SellHot AirAtaiBeckley Inc. · Healthcare · United States · $2.7B · Avg Vol: $88M/d
COMPANY DESCRIPTION
Atai Life Sciences N.V. (ATAI) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for mental health disorders, including depression, anxiety, and substance use. The company employs a decentralized platform model to identify, invest in, and advance a diverse pipeline of psychedelic and non-psychedelic compounds. This strategic approach aims to accelerate the development of innovative treatments for unmet medical needs in psychiatry.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.2M | 0.3M | 0.3M | 4.1M | 159.9% | 4.5M | 2.3M | -44.3% |
| EPS | -0.44 | -0.11 | -0.42 | -2.91 | — | -2.79 | — | — |
| Shares | 368.2M | 368.2M | 368.2M | 363.3M | -1.3% | 370.9M | — | — |
| Debt | 15.3M | 19.1M | 24.7M | 2.1M | -48.7% | 4.3M | — | — |
| Equity | 260.7M | 243.0M | 116.3M | 221.9M | -5.2% | — | — | — |
| Op CF | -104.5M | -84.1M | -82.4M | -102.7M | — | -127.1M | — | — |
| Inv CF | -86.8M | -53.3M | 59.2M | -109.1M | — | — | — | — |
| Fin CF | 20.8M | -8.4M | 5.4M | 269.5M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATAI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATAI | AtaiBeckley Inc.(you) | $2.7B | 23 | Sell |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.8B | 24 | Sell |
| NKTR | Nektar Therapeutics | $2.5B | 23 | Sell |
| IRON | Disc Medicine, Inc. | $3.1B | 22 | Sell |
| CLDX | Celldex Therapeutics, Inc. | $3.1B | 25 | Sell |
| NRIX | Nurix Therapeutics, Inc. | $2.7B | 28 | Sell |
| IMNM | Immunome, Inc. | $3.1B | 20 | Strong Sell |
| PGEN | Precigen, Inc. | $2.5B | 28 | Sell |
| MBX | MBX Biosciences, Inc. | $3.0B | 28 | Sell |
| TRVI | Trevi Therapeutics, Inc. | $2.4B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%